Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.

Abstract

The only US licensed vaccine with established efficacy against smallpox, Dryvax, is contraindicated for HIV patients. Detectable smallpox-neutralizing antibodies are still present among US adults. This study compared vaccinia-neutralizing antibody titers between 20 HIV-infected and 20 uninfected veterans matched for age and military entry. Vaccinia-neutralizing antibodies were detected in 95% HIV-infected and 100% uninfected veterans; 40% HIV-infected and 70% uninfected adults had protective titers. Therefore, after robust vaccination, neutralizing antibodies are maintained for prolonged times despite CD4 cell depletion.

• Authors: Virginia L Kan, Jody Manischewitz, Lisa R King, Hana Golding
• Journal: AIDS (London, England) (AIDS) Vol. 21 Issue 4 Pg. 521-4 (Feb 19 2007) ISSN: 0269-9370 [Print] England
• PMID: 17301573 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antibodies, Viral
• DryVax vaccine
• Smallpox Vaccine

Topics

• Adult
• Antibodies, Viral (blood)
• CD4 Lymphocyte Count
• Female
• HIV Infections (immunology)
• Humans
• Male
• Middle Aged
• Pilot Projects
• Smallpox Vaccine (immunology)
• Time Factors
• Vaccinia virus (immunology)
• Veterans